Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

U.S. government halts use of Lilly’s bamlanivimab monotherapy

By Brian Buntz | March 26, 2021

Eli Lilly The spread of SARS-CoV-2 variants has convinced the U.S. government to stop using Lilly’s COVID-19 monoclonal antibody therapy bamlanivimab when used alone.

The U.S. government will continue using bamlanivimab when paired with etesevimab, another monoclonal antibody.

The government pointed to the rising number of SARS-CoV-2 variants across the country as the reasoning behind the decision.

Lilly stresses that bamlanivimab and etesevimab together should offer stronger protection against SARS-CoV-2 variants than either when used alone.

Several variants can potentially reduce the neutralization by monoclonal antibody treatments, according to the CDC. Variants such as B.1.429 and B.1.427, which emerged in California, have significant resistance to neutralization from at least some monoclonal antibody therapies available in the U.S. The P.1 variant first spotted in Brazil, and the B.1.351 variant from South Africa have moderate resistance to such antibodies.

HHS had earlier announced that it would limit the distribution of bamlanivimab to three states with a high presence of SARS-CoV-2 variants with the potential to evade the monoclonal antibody.

Bamlanivimab won emergency use authorization from FDA for people at risk of developing severe COVID-19 infections.

Bamlanivimab was developed jointly by Eli Lilly and AbCellera.

 

 

Tell Us What You Think! Cancel reply

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards